H.C. Wainwright analyst Yi Chen initiated coverage of Regenxbio with a Buy rating and $36 price target. The company is focused on the development of gene therapies that enable the production of therapeutic proteins or antibodies for ophthalmic disorders and rare diseases, the analyst tells investors in a research note. The analyst says two pivotal trials of ABBV-RGX-314 in wet advanced neovascular are slated to report topline data in 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RGNX: